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Objectives
There remains conflicting evidence regarding cortical bone strength following 
bisphosphonate therapy. As part of a study to assess the effects of bisphosphonate 
treatment on the healing of rat tibial fractures, the mechanical properties and radiological 
density of the uninjured contralateral tibia was assessed.
Methods
Skeletally mature aged rats were used. A total of 14 rats received 1μg/kg ibandronate (iban) 
daily and 17 rats received 1 ml 0.9% sodium chloride (control) daily. Stress at failure and 
toughness of the tibial diaphysis were calculated following four-point bending tests.
Results
Uninjured cortical bone in the iban group had a significantly greater mean (standard 
deviation (SD)), p < 0.001, stress at failure of 219.2 MPa (SD 45.99) compared with the 
control group (169.46 MPa (SD 43.32)) following only nine weeks of therapy. Despite this, 
the cortical bone toughness and work to failure was similar. There was no significant 
difference in radiological density or physical dimensions of the cortical bone.
Conclusions
Iban therapy increases the stress at failure of uninjured cortical bone. This has relevance when 
normalising the strength of repair in a limb when comparing it with the unfractured limb. 
However, the 20% increase in stress at failure with iban therapy needs to be interpreted with 
caution as there was no corresponding increase in toughness or work to failure. Further research 
is required in this area, especially with the increasing clinical burden of low-energy diaphyseal 
femoral fractures following prolonged use of bisphosphonates.
Cite this article: Bone Joint Res 2015;4:99–104
Article focus
 To assess the effect of bisphosphonates
on the mechanical properties and radio-
logical density of cortical bone.
Key messages
 Bisphosphonate increases the stress at fail-
ure of cortical bone by up to 20% following
nine weeks of therapy. 
 This increase in stress at failure should be
interpreted with caution as there was no
corresponding increase in bone toughness
and work to failure.
 The effect of prolonged bisphosphonate
treatment on cortical bone needs further
study.
Strengths and limitations
 This is the first study to assess the effects
of bisphosphonates on cortical bone
which has used aged skeletally mature
animals. This is more representative of the
situation in routine clinical practice when
bisphosphonates are prescribed for the
prevention of fragility fractures in the
elderly population. 
 This study showed that the use of
bisphosphonates resulted in an increase
in the stress at failure in the unfractured
limb, however, as this was performed as a
single test to failure, the effect on the
fatigue properties of the bone were not
assessed. 
Freely available online
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 A potential source of error could arise from the deriva-
tion of the second moment of area. In this study, as
the cross section was assumed to be a triangle, and
measurement resolution was to ± 0.01 mm. μCT,
scanning of the limb could be used to determine the
exact shape and dimensions.
Introduction
The effect of bisphosphonates on bone is primarily via an
anti-catabolic effect owing to inhibition of osteoclast
mediated bone resorption. The effect of bisphosphonates
on the mechanical properties of cortical bone remain
poorly reported. Animal trials in rodents, canines and pri-
mates have consistently shown that bisphosphonates
increase the compressive load at failure of cancellous
bone within the vertebra1-6 and femoral neck.1,2 Prospec-
tive human studies7-9 have shown that bisphosphonates
prevent loss of bone mineral density (BMD) and decrease
the risk of fracture, particularly in cancellous bone at the
vertebral column and femoral neck. Recent randomised
double blind placebo controlled clinical studies10,11 have
even suggested an actual increase in BMD at these sites
with oral bisphosphonate taken once a month. However,
laboratory studies that demonstrate preservation of BMD
and an increase in cancellous bone compressive strength
with bisphosphonate therapy have not shown consistent
effects on cortical bending strength.1,12
The combination of findings in clinical trials and animal
data, in particular the demonstrable increase in strength
of cancellous bone and reduction in the risk of fracture,
has led to the widespread use of bisphosphonates in the
prevention of fractures.
The effect of bisphosphonate on the mechanical prop-
erties of cortical bone is of particular importance as corti-
cal bone remodels less quickly than cancellous bone. The
bisphosphonate inhibition of remodelling,13 with a resul-
tant accumulation of ‘micro-damage’,14 may manifest clini-
cally as cortical insufficiency fractures.13,15,16
The aim of this study was to identify the effect of
bisphosphonate administration on the mechanical prop-
erties and radiological density of cortical bone. Ibandro-
nate (iban) was administered at a therapeutic dose
known to prevent post-ovariectomy loss in BMD.17 Stress
at failure, work to failure, toughness of bone, physical
measurements of bone and radiological density of the tib-
ial diaphysis were assessed.
Materials and Methods
All animal procedures were approved by the Home Office
of the United Kingdom, and adhered to the Animals (Sci-
entific Procedures) Act 1986. In total, 31 skeletally mature
male ex-breeder Sprague-Dawley rats (Harlan, United
Kingdom) that were all aged > one year were included in
this randomised study, with the sample size based on a
power calculation for a fracture healing study. The rats
were fed standard rat chow and provided with water ad
libitum. They were housed in individual cages at a con-
stant temperature (21˚C; ± 1˚C) and humidity (45% to
55%) using a 12-hour light/dark cycle. Animals received
three weeks of daily subcutaneous injections prior to the
creation of a standardised right tibial osteotomy and
operative stabilisation with a plate and two bicortical
screws on either side as part of a fracture healing study.18
All animals were noted to mobilise freely with no restrictions
within 24 hours post-surgery. In total, 14 animals
received 1 μg/kg iban daily and the remaining 17 received
daily subcutaneous injections of 0.9% saline, which acted
as the control. The mean weight of iban and control rats
was 491.93 g (SD 55.4) and 508.12 g (SD 41.9), respectively.
Six weeks post-osteotomy, animals were sacrificed and
the left uninjured tibiae were carefully dissected free of
soft tissue for use in this study.
Plain radiographs were obtained using a portable
radiograph unit (Acu-Ray JR, Stern Manufacturing,
Toronto, Canada) with an output of 60 kV, 2 mAs and
exposure time of 0.1 ms. Images were captured on digital
radiograph plates (Fuji CR Cassette, Fuji Photo Film Co
Ltd, Japan). Lateral contact radiographs were obtained to
exclude the effect of fibula overlay in radiological analysis
of bone density. An aluminium step wedge consisting of
ten 1 mm steps was placed near the area of interest in
each radiograph. Subsequent image analysis was per-
formed in MATLAB (The MathWorks, Inc., Massachusetts).
For each rat, the point where the fibula joins the tibia dis-
tally was marked. A 100 × 50 pixel box was marked from
this point to include the mid shaft of the bone. To assess
bone density, an average grey level of the diaphyseal
tibia within this box was measured. This measured grey
level was then converted to an aluminium equivalent
(Al.Eq) density using a previously described method.19
Following plain radiographs, the samples were placed
in 0.9% saline within individual tubes and frozen at -
20˚C prior to mechanical testing which took place
within two weeks.20 Mechanical testing to failure with a
four-point bend was performed using a rig (Fig. 1)
designed for rat tibias (The University of Edinburgh Phys-
ics Workshop, Edinburgh, United Kingdom) in conjunc-
tion with a Zwick/Roell Z005 (Zwick GmbH & Co, Ulm,
Germany) materials testing machine. The upper loading
rig was mounted on a pivot to ensure symmetrical load-
ing of the irregularly shaped rat tibias at all four loading
points. The upper loading span was spaced 10 mm
apart and the lower static span was spaced 20 mm
apart. Contact points were rounded to minimise notch-
ing of the bone after load application. Specimens were
warmed in a water bath set at 37˚C for a minimum of 30
minutes prior to mechanical testing. Immediately
following removal from the water bath, the tibias were
mounted on the rig resting on the lateral surface and a
four-point bend applied while the bone was well
hydrated. The bones were observed during loading and
no rotation of the specimen was observed. A pre-load of
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1 N was applied to the bone before loading to failure at
a rate of 10 Ns-1 following the protocol set out in another
study,18 and a 5 kN load cell was used. A load-deflection
curve was obtained for each specimen during mechani-
cal testing. The area under this curve, up to the point of
failure, was derived to quantify work to failure.
Following failure, the tibial midshaft cross section
most closely resembled a triangle (Fig. 2). The sagittal
and coronal widths which corresponded to the vertical
height (H) and base length (B) of the triangular cross
section were obtained using sliding callipers. A digital
image (Canon Digital IXUS 75 camera) of the distal seg-
ment cross section for each sample was obtained. These
images were printed and the vertical height and base
length of the triangular cross section for the whole bone
and the intramedullary canal were measured manually.
The scale for the digital image was obtained by compar-
ing the external widths previously measured with the
callipers to the readings obtained from the image. The
internal vertical height (h) and base length (b) of the
triangular intramedullary cross section were then
calculated. The cross-sectional moment of inertia (INA)
was then derived using equation 1 (Fig. 3), in order to
facilitate the calculation of the stress because of bending
(σB), according to elastic beam bending theory
(equation 2, Fig. 4).
Theoretical strain was calculated with measurements
gathered during the four-point bending test as previ-
ously described.21 A stress–strain curve was plotted and
the area under this curve to the point of fracture was
measured to assess toughness as previously described.22
Two animals in the IBAN group were excluded from
analysis as failure occurred in a mode not consistent
with bending stress. 
Fig. 1
Photographs of four-point bending of the rat tibia.
h
b
H
B
Fig. 2
Photograph of triangular cross section of the tibia. (H, vertical height; B, base
length; h, internal vertical height; b, internal base length.)
=
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Fig. 3
Equation 1
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Equation 2
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Statistical analysis. This was performed using Minitab 16
(Minitab Inc, State College, Pennsylvania). The variables
were tested for normality using a Ryan–Joiner test. Peak
stress, toughness, physical measurements of cortical
bone and Al.Eq density were found to be normally distrib-
uted and were analysed using a one-way analysis of vari-
ance. Both work to failure and deflection were found to
be not normally distributed and were analysed using a
Kruskal–Wallis test for non-parametric data.
Results
Following nine weeks of treatment, prior to sacrifice, the
mean (SD) weight of iban and control rats was 504 g
(SD 69.15) and 505 g (SD 37.72), respectively (p = 0.53).
Stress at failure, toughness, physical measurements of
coronal and sagittal width and Al.Eq density measure-
ments for each animal are presented in Table I.
The iban group had a statistically significant (p = 0.006)
higher stress at failure (SD) 219.2 MPa (SD 45.99)
compared with the control group (169.5 MPa, SD 43.32)
(Fig. 5). There was a trend towards a greater toughness in
the iban group but this did not reach statistical
significance (p = 0.093) (iban vs control = 2.51 MJ/mm3,
SD 1.74 vs 1.67 MJ/mm3, SD 0.86). Similarly, there was a
greater, but not statistically significant (p = 0.094), mean
work to failure in the iban group compared with controls.
The deformation to the point of fracture was greater in
the iban group, but not significantly different (p = 0.081)
(iban vs control = 0.68 mm, SD 0.23; vs 0.55 mm, SD 0.27).
There was no statistically significant difference in the
physical measurements of bone width. The mean (SD)
coronal and sagittal cortical bone widths for the iban ver-
sus control groups were 3.7 mm (SD 0.83) versus 3.8 mm
(SD 0.62) and 2.7 mm (SD 0.24) versus 3.0 mm (SD 0.21),
respectively. There was no difference in the cross sectional
moment of inertia between the groups (iban vs control =
0.97 mm4, SD 0.07 vs 1.01 mm4, SD 0.08).
There was no statistically significant difference in the
mean (SD) Al.Eq density at the tibial diaphysis (iban vs
control = 1.53, SD 0.24 vs 1.76, SD 0.33). A scatter plot of
the relationship between Al.Eq density and stress at fail-
ure is presented in Figure 6.
Discussion
There is conflicting evidence regarding the effect of
bisphosphonates on the mechanical properties of cortical
bone. In growing rats, both a short bisphosphonate
period of treatment of three weeks with pamidronate23
and a longer duration of up to two years with
alendronate3 have been shown to increase femoral
cortical strength in three-point bending stress tests
compared with healthy controls. In ovariectomised rats,
three months of clodronate24 and one year of zoledronic
acid25 increased femoral24,25 and tibial24 cortical bending
strength in comparison with sham-ovariectomised
controls. However, six months of alendronate therapy in
Table I. Mechanical properties, physical dimensions and aluminium
equivalent (Al.Eq) measurements of density for each animal
Property Mean iban (SD) Mean control (SD) p-value
Stress (MPa) 219.2 (46.0) 169.5 (43.3) 0.006
Work (mJ) 77.2 (50.5) 52.9 (23.9) 0.094
Toughness (J/m3) 2.51 (1.74) 1.66 (0.86) 0.093
Deflection (mm) 0.804 (0.480) 0.549 (0.274) 0.081
Coronal width (mm) 3.70 (0.82) 3.83 (0.61) 0.627
Sagittal width (mm) 2.87 (0.23) 3.03 (0.22) 0.066
Al.Eq density (mm) 1.53 (0.27) 1.75 (0.36) 0.074
Iban, ibandronate;SD, standard deviation
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Fig. 5
Graph showing the stress at failure of rats treated with ibandronate
(iban) versus control.
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Graph showing scatter plot of stress at failure versus density of the aluminium
equivalent (Al.Eq; Iban, ibandronate).
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ovariectomised rats did not affect femoral diaphyseal
strength in bending tests, despite the increased
mechanical strength noted in cancellous bone tested in
compression.2 Similarly, six months of alendronate26 in
castrated male rats did not increase bending strength of
the femur diaphysis, despite the improved strength noted
previously in ovariectomised rats that received a similar
dosing regimen.3
The differing results may be because previous studies
in rodents have used ovariectomised2,24,25 skeletally
immature models3,23,26 or castrated skeletally immature
animals26 whereby a sufficient period of time27,28
between castration and the experimental period was not
observed to permit development of osteopaenia post
castration. The effect of bisphosphonate on growing
bone is unlikely to resemble the clinical scenario of
bisphosphonate treatment for fragility fracture prevention
in the elderly. In the rodent, ovariectomy has been shown
to increase bone formation in tibial cortical bone29 and
results in elevated tibial bending strength up to six months
post-ovariectomy.24 Therefore, an ovariectomised model
was not used as it may have confounded our results. 
To our knowledge, this is the first study to use aged
ex-breeder animals which is more representative of the
situation in routine clinical practice when bisphosphonates
are prescribed for the prevention of fragility fractures in
the elderly population. Skeletally mature animals were
also used to eliminate possible differing effects of
bisphosphonate on growing bone. In all animals used
within this study, both the proximal and distal tibial
epiphyses had fused. 
Contrary to the often stated opinion that bone
remodelling does not occur in the rat,30,31 Bentolila et al32
observed bone remodelling following fatigue loading of
rodent ulnas. After ten days of axial loading, there was a
strong association between linear ‘microcracks’ and
osteoclastic-led tunnelling units. In addition, 40% fewer
‘microcracks’ were observed compared with the similarly
loaded contralateral ulna immediately before the rodents
were killed. This suggested that the ‘microcracks’ were
being repaired by a process of bone remodelling as seen
with the Haversian technique. 
It is known that following a fracture, osteopaenia is
detectable as a decrease in bone mineral density (BMD) in
the contralateral uninjured limb.33 Our results indicate that
iban at a therapeutic dose17 may increase stress of cortical
bone at failure despite the expected fracture-induced
osteopaenia. Our finding differs to that previously
reported in a beagle dog model of long bone fracture,
where alendronate therapy at a high non-therapeutic
dose did not affect the rate of stress at failure either of
the healing fractured radius or the contralateral radial
diaphysis.34 
Our results suggest that within the total of nine weeks
of iban therapy, the mean stress at failure of cortical bone
is increased by greater than 20%. There was also no
difference in the cortical bone physical dimensions. It
may be that the regions of remodelling bone that are
undergoing resorption by osteoclasts do not contribute
to the mechanical strength of the bone. Therefore, the
rapid increase in bone strength with bisphosphonate
treatment could be accounted for by these regions that
are now able to contribute to the mechanical strength of
the bone as they are no longer resorbed by osteoclasts. 
A previous study using cortical femoral specimens from
human donors reported a linear relationship between the
decrease in bone strength and toughness with ageing.35
Therefore, the authors concluded that with respect to
age-related change in bone material properties, the
relationship between bone strength and toughness is
linear, and thus similar to that seen in synthetic fibre
composites.36 We found that despite an increase in bone
strength of more than 20% following nine weeks of
bisphosphonate therapy, the toughness of bone and
work to failure did not change significantly, suggesting
that the energy absorbed per unit of bone prior to failure
changed less than the absolute strength. This increase in
strength, but not in toughness, may indicate that for
patients on bisphosphonates, hip protection devices
should focus on reducing the energy transmitted to the
bone in order to provide the maximum synergistic benefit
in fracture reduction.
Despite the significant positive effect of iban therapy
on the stress at failure of rat tibia cortical bone in bending
tests, no statistically significant effect was noted in the
radiological assessment of bone density. The mechanical
properties may be altered prior to detectable radiological
change or the method used in this study was not able to
detect subtle changes in radiological density, especially in
that of small bones. Perhaps the use of micro-computed
tomography analysis may have detected a less obvious
difference. Whatever the cause for the increase in
strength, the observed effect of a bisphosphonate on the
mechanical properties of the uninjured limb needs to be
considered when reporting proportional strength of
fracture repair compared with the unfractured limb, as it
is often used in fracture healing studies. 
This study demonstrates that iban therapy increases
the stress at failure of cortical bone in the uninjured limb
in the early phase following a fracture. It is increasingly
evident that a large proportion of osteoporotic fractures
occur at non-vertebral sites of predominant cortical bone
and is due to the significant cortical bone loss that occurs
in osteoporosis.37 The observed increase in stress at
failure of cortical bone with iban treatment is encourag-
ing. However, the lack of a similar beneficial effect on
toughness of bone and work to failure should be borne in
mind. The effect of prolonged bisphosphonate treatment
on cortical bone, especially in the longer term, needs to
be studied further, especially in view of reports of low-
energy subtrochanteric femoral fractures following
continuous long-term use of bisphosphonates.13,15,16
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